Cian Healthcare Limited has announced that its Board of Directors approved a revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) during a meeting held on March 16, 2026. The decision was communicated to BSE Limited through an official intimation pursuant to Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

Board Meeting Outcome

The Board meeting (CHL/BM/2025-26/01) was conducted physically on March 16, 2026, where directors considered and approved the revised code. Company Secretary and Chief Compliance Officer Rachit Malhotra (Membership No.: A39894) signed the official communication, confirming the approval and submission of the revised code as Annexure-A to the stock exchange.

Key Features of the Revised Code

The comprehensive code establishes a structured framework for handling UPSI and ensures compliance with regulatory requirements. The document defines critical roles, including the Chief Investor Relations Officer (CIRO), who will be responsible for proper and timely dissemination of information and determination of whether particular information constitutes UPSI.

Principles of Fair Disclosure

The revised code outlines several key principles that the company must adhere to:

• Prompt dissemination of UPSI that would impact price discovery as soon as credible information becomes available
• Uniform and universal dissemination through stock exchanges and company website before releasing to media or analysts
• Handling all UPSI on a need-to-know basis with appropriate safeguards
• Ensuring employees do not respond to inquiries unless authorized by CIRO
• Making public announcements only after final or definitive decisions are taken

Compliance and Protection Measures

The code establishes comprehensive protection against retaliation and victimization for employees who file Voluntary Information Disclosure Forms with SEBI. It ensures that such employees cannot be discriminated against, discharged, terminated, or harassed for cooperating with regulatory authorities or participating in enforcement actions.

The company will maintain a structured digital database (SDD) containing details of UPSI sharing, including names of persons involved, their contact information, and relevant documentation. This database must be preserved for at least 8 years after completion of relevant transactions, with adequate systems to prevent tampering.

Regulatory Framework

The revised code incorporates definitions and requirements from multiple regulatory frameworks, including the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Companies Act 2013, and related amendments. It establishes clear guidelines for determining legitimate purposes for sharing UPSI and ensures compliance with evolving regulatory requirements.

The audit committee will review compliance with the code at least once annually and verify the adequacy of internal control systems. The Board retains authority to amend the code as necessary to maintain compliance with applicable laws and regulations.

Source: None/Company/INE05BN01019/36ee858e-06f1-4f73-b078-8f658e101a1c.pdf

Cian Healthcare Limited has announced the relocation of its corporate office from Pune to New Delhi, marking a significant operational shift for the healthcare company. The decision was formally approved by the Board of Directors and communicated to BSE Limited in compliance with regulatory requirements.

Board Approval and Timeline

The Board of Directors of Cian Healthcare Limited approved the corporate office relocation during their physical meeting held on March 16, 2026. The meeting commenced at 02:00 P.M. (IST) and concluded at 03:38 P.M. (IST), with the relocation taking effect immediately from March 16, 2026.

Office Relocation Details

The company has provided specific details regarding the address change in its regulatory filing:

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026.

The announcement was signed by Rachit Malhotra, Company Secretary and Chief Compliance Officer (Membership No.: A39894), and submitted to BSE Limited under reference number CIAN/BSE/2025-26/23. The company trades on BSE with scrip code 542678 and trading symbol CHCL.